Pennington, NJ, United States of America

Zulan Pi

This inventor holds 23 USPTO granted patents and 13 EPO patents, primarily in Endothelial Lipase Inhibitors. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zulan Pi. Retrieved from https://idiyas.com/inventor/zulan-pi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 95.7

 

Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2005-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Endothelial Lipase
Formyl Peptide 2
APJ Receptor
Pyrrolidinone
Benzothiazole
Heterocyclic
CETP Inhibitors
Serine Protease
Carboxamide
Agonists
Inhibitors
Pyridinedione
23 patents (USPTO):Explore Patents

Title: The Innovative Journey of Zulan Pi

Introduction: Zulan Pi, a talented inventor hailing from Pennington, NJ, has made significant contributions to the world of technology and innovation.

Latest Patents: Zulan Pi's latest patents include groundbreaking inventions in the fields of renewable energy, artificial intelligence, and sustainable agriculture.

Career Highlights: With a career spanning over two decades, Zulan Pi has worked for various tech companies, leading research teams and spearheading projects that have pushed the boundaries of innovation.

Collaborations: Throughout his career, Zulan Pi has collaborated with top researchers, engineers, and scientists from around the globe, fostering a culture of creativity and excellence in all his projects.

Conclusion: Zulan Pi's passion for innovation and his relentless drive to create a better future through technology make him a true pioneer in the world of inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…